dc.contributor.author | Goggin, C | |
dc.contributor.author | Stansfeld, A | |
dc.contributor.author | Mahalingam, P | |
dc.contributor.author | Thway, K | |
dc.contributor.author | Smith, MJ | |
dc.contributor.author | Huang, P | |
dc.contributor.author | Jones, RL | |
dc.contributor.author | Napolitano, A | |
dc.coverage.spatial | England | |
dc.date.accessioned | 2022-09-27T11:47:08Z | |
dc.date.available | 2022-09-27T11:47:08Z | |
dc.date.issued | 2022-07-26 | |
dc.identifier.citation | Future Oncology, 2022, 18 (26), pp. 2967 - 2978 | |
dc.identifier.issn | 1479-6694 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/5507 | |
dc.identifier.eissn | 1744-8301 | |
dc.identifier.eissn | 1744-8301 | |
dc.identifier.doi | 10.2217/fon-2022-0226 | |
dc.description.abstract | Over the past 20 years, the management of gastrointestinal stromal tumors has acted as an important model in the advancement of molecularly targeted therapies for solid tumors. The success of imatinib has established it as a lasting therapy in the management of early-stage and advanced disease in the first-line setting. Imatinib resistance inevitably develops, resulting in the need for further lines of therapy. Ripretinib is an orally administered switch-control tyrosine kinase inhibitor, specifically developed to target both primary and secondary KIT and PDGFRα resistance mutations. Herein, the authors discuss the molecular rationale, the preclinical evidence and the clinical use of ripretinib in the treatment of gastrointestinal stromal tumors in the advanced stages of disease. | |
dc.format | Print-Electronic | |
dc.format.extent | 2967 - 2978 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | FUTURE MEDICINE LTD | |
dc.relation.ispartof | Future Oncology | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | |
dc.subject | DCC-2618 | |
dc.subject | GIST | |
dc.subject | INTRIGUE | |
dc.subject | INVICTUS | |
dc.subject | KIT | |
dc.subject | PDGFR | |
dc.subject | resistance mutation | |
dc.subject | ripretinib | |
dc.subject | Antineoplastic Agents | |
dc.subject | Drug Approval | |
dc.subject | Drug Resistance, Neoplasm | |
dc.subject | Gastrointestinal Neoplasms | |
dc.subject | Gastrointestinal Stromal Tumors | |
dc.subject | Humans | |
dc.subject | Imatinib Mesylate | |
dc.subject | Mutation | |
dc.subject | Naphthyridines | |
dc.subject | Protein Kinase Inhibitors | |
dc.subject | Proto-Oncogene Proteins c-kit | |
dc.subject | Urea | |
dc.title | Ripretinib in advanced gastrointestinal stromal tumors: an overview of current evidence and drug approval. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2022-06-24 | |
dc.date.updated | 2022-09-27T11:46:23Z | |
rioxxterms.version | VoR | |
rioxxterms.versionofrecord | 10.2217/fon-2022-0226 | |
rioxxterms.licenseref.startdate | 2022-07-26 | |
rioxxterms.type | Journal Article/Review | |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/35880452 | |
pubs.issue | 26 | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Molecular and Systems Oncology | |
pubs.publication-status | Published | |
pubs.publisher-url | http://dx.doi.org/10.2217/fon-2022-0226 | |
pubs.volume | 18 | |
icr.researchteam | Translational Sarcoma, Melanoma and Rare Tumour Surgery | |
icr.researchteam | Mol and Systems Oncology | |
dc.contributor.icrauthor | Smith, Myles | |
dc.contributor.icrauthor | Huang, Paul | |
icr.provenance | Deposited by Mr Arek Surman on 2022-09-27. Deposit type is initial. No. of files: 1. Files: fon-2022-0226.pdf | |